Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease

Siddique, Yasir Hasan; Naz, Falaq; Rahul, .; Varshney, Himanshi

doi:10.1016/j.crphar.2022.100120

Cited by 7 publications

(5 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current findings demonstrated that Riva-administered rats had decreased caspase-3 genetic expression. Similar findings were made by Siddique et al (2022) 33 on the upregulation of caspase-3 in the L-arginine group and Riva's ability to decrease caspase-3 and 9 gene expression, which is a measure of apoptosis.…”

Section: Discussionsupporting

confidence: 87%

Protective effect of rivastigmine against lung injury in acute pancreatitis model in rats via Hsp 70/IL6/ NF-κB signaling cascade

Yehia Kamel,

Zekry Attia,

Mahmoud Ahmed

et al. 2023

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Acute lung injury (ALI) that develops as a result of AP can progress to acute respiratory distress syndrome. Some hypotheses are proposed to explain the pathophysiology of AP and its related pulmonary hazards. This experiment aimed to evaluate the mitigating action of rivastigmine (Riva) in lung injury that occurs on the top of acute pancreatitis (AP) induced in rats. Thirty-two male Wister rats were randomized to one of four groups: control, Riva-treated, acute pancreatitis (AP), and acute pancreatitis treated by Riva. Serum amylase and lipase levels were assessed. Pulmonary oxidative stress and inflammatory indicators were estimated. A pancreatic and pulmonary histopathological examination, as well as an immunohistochemical study of HSP70, was carried out. Riva significantly attenuated the L-arginine-related lung injury that was characterized by increased pulmonary inflammatory biomarkers (interleukin-6 [IL‐6]), nuclear factor kappa B (NF‐κB), tumor necrosis factor‐α (TNF‐α), increased pulmonary oxidative markers (total nitrite/nitrate [NOx]), MDA, decreased total antioxidant capacity (TAC), and reduced glutathione level (GSH)) with increased caspase-3 expression. Therefore, Riva retains potent ameliorative effects against lung injury that occur on the top of AP by relieving oxidative stress, inflammation, and apoptosis via HSP70/IL6/NF-κB signaling.

show abstract

Section: Discussionsupporting

confidence: 87%

Protective effect of rivastigmine against lung injury in acute pancreatitis model in rats via Hsp 70/IL6/ NF-κB signaling cascade

Yehia Kamel,

Zekry Attia,

Mahmoud Ahmed

et al. 2023

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…While galantamine and rivastigmine are reported to slow the decline in cognition and improve cognition (Li et al, 2019 ; Agbomi et al, 2022 ), rivastigmine may be slightly more efficacious than galantamine (Siddique et al, 2022 ) among female AD, VaD, and MVAD patients. The pharmacokinetics and pharmacodynamics of drugs vary in females and males (Soldin and Mattison, 2009 ).…”

Section: Discussionmentioning

confidence: 99%

Differences in pharmacologic and demographic factors in male and female patients with vascular dementia, Alzheimer's disease, and mixed vascular dementia

et al. 2023

View full text Add to dashboard Cite

BackgroundIncreasing evidence suggests that demographic and pharmacologic factors may play a significant role in the epidemiology of dementia. Sex differences in prevalence also depend on dementia subtypes, such as Alzheimer's dementia (AD), vascular dementia (VaD), and mixed vascular-Alzheimer's dementia (MVAD). Therefore, studies are needed to investigate sex-specific differences, and identify potential therapeutic targets for both sexes.MethodsData was collected from the Prisma Health-Upstate Alzheimer's registry from 2016 to 2021 for 6,039 VaD patients, 9,290 AD patients, and 412 MVAD patients. A logistic regression was used to determine demographic and pharmacological factors associated with gender differences in patients with VaD, AD, and MVAD.ResultsIn patients with VaD, African Americans (OR = 1.454, 95% CI, 1.257–1.682, p < 0.001) with increasing age (OR = 1.023, 95% CI, 1.017–1.029, p < 0.001), treated with aripiprazole (OR = 4.395, 95% CI, 2.880–6.707, p < 0.001), were associated with females, whereas patients treated with galantamine (OR = 0.228, 95% CI, 0.116–0.449, p < 0.001), memantine (OR = 0.662, 95% CI, 0.590–0.744, p < 0.001), with a history of tobacco (OR = 0.312, 95% CI, 0.278–0.349, p < 0.001), and ETOH (OR = 0.520, 95% CI, 0.452–0.598, p < 0.001) were associated with males. Among AD patients, African Americans (OR = 1.747, 95% CI, 1.486–2.053, p < 0.001), and Hispanics (OR = 3.668, 95% CI, 1.198–11.231, P = 0.023) treated with buspirone (OR = 1.541, 95% CI, 1.265–1.878, p < 0.001), and citalopram (OR = 1.790, 95% CI, 1.527–2.099, p < 0.001), were associated with females, whereas patients treated with memantine (OR = 0.882, 95% CI, 0.799–0.974, p = 0.013), and with a history of tobacco (OR = 0.247, 95% CI, 0.224–0.273, p < 0.001), and ETOH (OR = 0.627, 95% CI, 0.547–0.718, p < 0.001) were associated with male AD patients. In patients with MVAD, rivastigmine (OR = 3.293, 95% CI, 1.131–9.585, p = 0.029), memantine (OR = 2.816, 95% CI, 1.534–5.168, p < 0.001), and risperidone (OR = 10.515, 95% CI, 3.409–32.437, p < 0.001), were associated with females while patients with an increased length of stay (OR = 0.910, 95% CI, 0.828–1.000, p = 0.049), with a history of tobacco (OR = 0.148, 95% CI, 0.086–0.254, p < 0.001) and ETOH use (OR = 0.229, 95% CI, 0.110–0.477, p < 0.001) were more likely to be associated with males.ConclusionsOur study revealed gender differences and similarities in the demographic and pharmacological factors of VaD, AD, and MVAD. Prospective studies are needed to determine the role of demographic and pharmacological factors in reducing sex-based disparities among VaD, AD, and MVAD patients.

show abstract

“…Drosophila models of amyloid toxicity have also been used to identify and screen potential therapeutic targets. Drosophila has been employed to investigate the impact of approved acetylcholine esterase inhibitors (aChEIs), such as rivastigmine, on amyloid toxicity and recently synthesised aChEIs (Siddique & Naz, 2022;Uras et al, 2021).…”

Section: Quas-aβ42arcmentioning

confidence: 99%

Using Drosophila amyloid toxicity models to study Alzheimer's disease

Tsintzas,

Niccoli

2024

Annals of Human Genetics

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most prevalent form of dementia and is characterised by a progressive loss of neurons, which manifests as gradual memory decline, followed by cognitive loss. Despite the significant progress in identifying novel biomarkers and understanding the prodromal pathology and symptomatology, AD remains a significant unmet clinical need. Lecanemab and aducanumab, the only Food and Drug Administration approved drugs to exhibit some disease‐modifying clinical efficacy, target Aβ amyloid, underscoring the importance of this protein in disease aetiology. Nevertheless, in the absence of a definitive cure, the utilisation of preclinical models remains imperative for the identification of novel therapeutic targets and the evaluation of potential therapeutic agents. Drosophila melanogaster is a model system that can be used as a research tool to investigate neurodegeneration and therapeutic interventions. The short lifespan, low price and ease of husbandry/rearing make Drosophila an advantageous model organism from a practical perspective. However, it is the highly conserved genome and similarity of Drosophila and human neurobiology which make flies a powerful tool to investigate neurodegenerative mechanisms. In addition, the ease of transgenic modifications allows for early proof of principle studies for future therapeutic approaches in neurodegenerative research. This mini review will specifically focus on utilising Drosophila as an in vivo model of amyloid toxicity in AD.

show abstract

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease

Cited by 7 publications

References 71 publications

Protective effect of rivastigmine against lung injury in acute pancreatitis model in rats via Hsp 70/IL6/ NF-κB signaling cascade

Protective effect of rivastigmine against lung injury in acute pancreatitis model in rats via Hsp 70/IL6/ NF-κB signaling cascade

Differences in pharmacologic and demographic factors in male and female patients with vascular dementia, Alzheimer's disease, and mixed vascular dementia

Using Drosophila amyloid toxicity models to study Alzheimer's disease

Contact Info

Product

Resources

About